Congress Materials

FILTER
Select topic(s):
Content type:
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
A network meta-analysis of cumulative clinical benefit of anti-IL biologics for the treatment of moderate to severe psoriasis over 48–52 weeks
Richard B. Warren, April Armstrong, Mark Lebwohl, et al.
A Systematic Literature Review of Health-Related Quality of Life and Other Patient Reported Outcomes Across Key Subgroups in Hidradenitis Suppurativa
Alexa B Kimball, Joslyn S. Kirby, John R. Ingram, et al.
Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Xenofon Baraliakos, Sofia Ramiro, Marina Magrey, et al.
Achieving Increasingly Stringent Clinical Disease Control Criteria is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controll
Jessica A. Walsh, Laura C. Coates, Philip J. Mease, et al.
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomize
Marina Magrey, Atul Deodhar, Philip J. Mease, et al.
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Martin Rudwaleit, Filip Van den Bosch, Helena Marzo-Ortega, et al.
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Martin Rudwaleit, Filip Van den Bosch, Helena Marzo-Ortega, et al.
Assessment of the Performance of the IHS4-55 Using Data from a Phase 2 Study of Bimekizumab in Patients with Hidradenitis Suppurativa
Thrasyvoulos Tzellos, Athanassios Kyrgidis, Afsaneh Alavi, et al.
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
Sandra McBride, Jolanta Węgłowska, Peter Wolf, et al.
Association of DLQI 0/1 with relative PASI improvements in subgroups of patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT)
Sandra McBride, Jolanta Węgłowska, Peter Wolf, et al.
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Marina Magrey, Marleen G.H. Van de Sande, Maxime Breban, et al.
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
Andrew Blauvelt, Joseph F. Merola, Georgios Kokolakis, et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Andrew Blauvelt, Curdin Conrad, Antonio Costanzo, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension
Diamant Thaci, Ron Vender, Menno de Rie, et al.
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension
Diamant Thaci, Ron Vender, Menno de Rie, et al.
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Andrew Blauvelt, Linda Stein Gold, Melinda Gooderham, et al.
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Andrew Blauvelt, Linda Stein Gold, Melinda Gooderham, et al.
Bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: Pooled results through two years from the BE SURE and BE RADIANT phase 3 trials
Joseph F. Merola, Alice B. Gottlieb, Akimichi Morita, et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
April Armstrong, Steven Feldman, Paolo Gisondi, et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
Alice B. Gottlieb, Akihiko Asahina, Tsen F. Tsai, et al.
Bimekizumab efficacy over two years in patients with moderate to severe plaque psoriasis with scalp and nail involvement who switched from adalimumab, ustekinumab, or secukinumab: Results from the BE SURE, BE VIVID, BE BRIGHT, and BE RADIANT phase 3/3b tr
Richard B. Warren, Bruce Strober, Andreas Pinter, et al.
Bimekizumab efficacy through 96 weeks in patients with moderate to severe plaque psoriasis: Patient-reported outcomes from the BE RADIANT phase 3b trial
Georgios Kokolakis, Richard G. Langley, Alice B. Gottlieb, et al.
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
Mark Lebwohl, April Armstrong, Joseph F. Merola, et al.
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
Mark Lebwohl, April Armstrong, Joseph F. Merola, et al.
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Akimichi Morita, Joseph F. Merola, Laura C. Coates, et al.
Bimekizumab improved efficacy measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE
Alice B. Gottlieb, Akihiko Asahina, Joseph F. Merola, et al.
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Yoshinori Umezawa, Joseph F. Merola, Laura C. Coates, et al.
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Philip J. Mease, Laura C. Coates, Robert Landewé, et al.
Bimekizumab Improves Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Philip J. Mease, Atul Deodhar, Maxime Dougados, et al.
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Maureen Dubreuil, Karl Gaffney, Lianne S. Gensler, et al.
Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo-Controlled Study
D. van der Heijde, Xenofon Baraliakos, Maxime Dougados, et al.
Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy and Safety from a Phase 3, Multicenter, Randomized, Placebo-Controlled Study
Atul Deodhar, Desiree van der Heijde, Lianne S. Gensler, et al.
Bimekizumab in bDMARD-naïve patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo-controlled, active reference study
Joseph F. Merola, Akihiko Asahina, Paolo Gisondi, et al.
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
Joseph F. Merola, Xenofon Baraliakos, Diamant Thaci, et al.
Bimekizumab in patients with active non-radiographic axial spondyloarthritis and active ankylosing spondylitis: 24-week efficacy and safety from the BE MOBILE phase 3 studies
Diamant Thaci, Xenofon Baraliakos, Joseph F. Merola, et al.
Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab
Jennifer Soung, David Rosmarin, Anna Lopez Ferrer, et al.
Bimekizumab in patients with psoriatic arthritis: 3-year results for overall and tumor necrosis factor inhibitor (TNFi)-naïve populations from a phase 2b open-label extension study
Philip J. Mease, Atul A. Deodhar, Joseph F. Merola, et al.
Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials
April Armstrong, Richard G. Langley, Kenneth B. Gordon, et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from BE OPTIMAL, a Phase 3, Active Reference Study
William Tillett, Joseph F. Merola, Yoshiya Tanaka, et al.
Bimekizumab Maintained Improvements in Efficacy Endpoints and Had a Consistent Safety Profile Through 52 Weeks in Patients with Axial Spondyloarthritis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Fabian Proft, Desiree van der Heijde, Xenofon Baraliakos, et al.
Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos, Atul Deodhar, D. van der Heijde, et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open- label extension trial
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Xenofon Baraliakos, Victoria Navarro-Compán, Denis Poddubnyy, et al.
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
Richard G. Langley, Pablo Fernandez-Peñas, James Krueger, et al.
Bimekizumab safety and tolerability in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in five phase 3/3b clinical trials
Kenneth B. Gordon, Melinda Gooderham, Peter Foley, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Richard B. Warren, Yukari Okubo, Lynda Spelman, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Diamant Thaci, Shinichi Imafuku, Melinda Gooderham, et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
A. Blauvelt, K.C. Duffin, N. Magnolo, et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Andrew Blauvelt, Kristina Callis Duffin, Nina Magnolo, et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
A. Blauvelt, K.C. Duffin, N. Magnolo, et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
A. Blauvelt, K.C. Duffin, N. Magnolo, et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Andrew Blauvelt, Kristina C. Duffin, Nina Magnolo, et al.
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Dafna D. Gladman, Lars E. Kristensen, Diamant Thaci, et al.
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes, et al.
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes, et al.
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Joseph F. Merola, Robert Landewé, Iain B. McInnes, et al.
Bimekizumab Treatment Resulted in Clinically Meaningful Improvements in the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Scores Using Pooled Results from Two Phase 3 Trials in Patients with Psoriatic Arthritis
Laure Gossec, Laura C. Coates, Ana‐Maria Orbai, et al.
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni, Philip J. Mease, Joseph F. Merola, et al.
Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
Richard B. Warren, Curdin Conrad, Peter Foley, et al.
Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
Kilian Eyerich, Alice B. Gottlieb, Stefano Piaserico, et al.
Bimekizumab versus secukinumab in plaque psoriasis: Cumulative clinical and health‑related quality of life benefit through 2 years of the BE RADIANT phase 3b trial and open‑label extension
Mark Lebwohl, Patrick M. Brunner, Jennifer Soung, et al.
Both IL-17RA and IL-17RC receptor complexes are required for IL-17A- and IL-17F-driven inflammation
A. Maroof, A. Manghera, S. Shaw
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos, Pedro M. Machado, Lars Bauer, et al.
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos, Pedro M. Machado, Lars Bauer, et al.
Efficacy and safety of bimekizumab in bDMARD-naïve patients with psoriatic arthritis: 24-week results from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study
Joseph F. Merola, Akihiko Asahina, Frank Behrens, et al.
Efficacy and safety of bimekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: 16-week results from BE COMPLETE, a phase 3, randomised, double-blind placebo-controlled study
Richard B. Warren, Akihiko Asahina, Paolo Gisondi, et al.
Efficacy of bimekizumab in patients with psoriasis and skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials
Andrew Alexis, Raj Chovatiya, Leah Davis, et al.
Medical Symposium Winter Clinical, 2023
Family Matters: The central role of the IL-17 family of cytokines in inflammatory diseases
April Armstrong
Identification of Responder and Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis
Laure Gossec, Laura C. Coates, Ana-Maria Orbai, et al.
Impact of the CIMplicity® Patient Support Program on Persistence to Certolizumab Pegol Treatment: A Retrospective Cohort Analysis of Claims Data in the United States
Aimee Near, Srihari Jaganathan, Chao Song, et al.
Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
Matthias Augustin, Richard G. Langley, Richard B. Warren, et al.
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
Andreas Pinter, Matthias Augustin, David Pariser, et al.
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Philip C. Robinson, Walter P. Maksymowych, Lianne S. Gensler, et al.
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit, Matthew A. Brown, Floris Alexander van Gaalen, et al.
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Mark Lebwohl, et al.
Neutrophils and the IL-17 Axis Play a Key Pathological Role in Hidradenitis Suppurativa
Matthew Page, Hannah Edwards, Remi Okoye, et al.
Patient-reported quality of life in patients with psoriasis with skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials
George Han, Raj Chovatiya, Leah Davis, et al.
Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry
Philip J. Mease, Eric Jones, Adam Sima, et al.
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Joeri Nicolaes, Evi Tselenti, Theodore Aouad, et al.
Resolution of Enthesitis and Peripheral Arthritis with Bimekizumab in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 Studies
Marina Magrey, Marleen G.H. Van de Sande, Maxime Breban, et al.
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Alice B. Gottlieb, Julia-Tatjana Maul, Lynda Spelman, et al.
Single-cell sequencing of freshly isolated cells from lesional and peri-lesional skin to explore cellular origins of IL-17 isoforms in psoriasis
Andrew Skelton, Karin Pappelbaum, Xiaolin Li, et al.
Stable plasma concentration of certolizumab pegol is associated with clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Luis Puig, Paolo Gisondi, Andreas Pinter, et al.
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Luis Puig, Paolo Gisondi, Andreas Pinter, et al.
Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and its Open-Label Extension up to 1 Year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Treatment Journey of Patients with Non-Radiographic Axial Spondyloarthritis in a US Rheumatology Office Setting: A Retrospective Chart Review
Robert Low, Sari Hopson, Silky Beaty, et al.
Understanding the Pathobiology of Axial Spondyloarthritis and Psoriatic Arthritis
Kristine Kuhn
Validation of the HS-IGA: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials
Amit Garg, Carla Zema, Valerie Ciaravino, et al.